TrovaGene, Inc. (TROV) Given a $4.00 Price Target at Maxim Group
Separately, Cantor Fitzgerald reiterated an overweight rating on shares of TrovaGene in a report on Tuesday, August 8th.
Shares of TrovaGene (NASDAQ TROV) traded down 5.5529% on Thursday, reaching $0.8028. The company had a trading volume of 38,233 shares. The company has a 50 day moving average price of $1.04 and a 200 day moving average price of $1.22. The stock’s market capitalization is $29.92 million. TrovaGene has a 52-week low of $0.61 and a 52-week high of $5.98.
COPYRIGHT VIOLATION NOTICE: “TrovaGene, Inc. (TROV) Given a $4.00 Price Target at Maxim Group” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/08/14/trovagene-inc-trov-given-a-4-00-price-target-at-maxim-group.html.
Large investors have recently modified their holdings of the company. LMR Partners LLP acquired a new stake in shares of TrovaGene during the second quarter worth about $151,000. Two Sigma Securities LLC boosted its stake in shares of TrovaGene by 262.4% in the first quarter. Two Sigma Securities LLC now owns 120,516 shares of the medical research company’s stock worth $139,000 after buying an additional 87,264 shares in the last quarter. Finally, KCG Holdings Inc. boosted its stake in shares of TrovaGene by 560.1% in the first quarter. KCG Holdings Inc. now owns 210,301 shares of the medical research company’s stock worth $242,000 after buying an additional 178,440 shares in the last quarter. Hedge funds and other institutional investors own 15.14% of the company’s stock.
TrovaGene Company Profile
Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.
Receive News & Stock Ratings for TrovaGene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene Inc. and related stocks with our FREE daily email newsletter.